Biotech startup Orna Therapeutics has cut more jobs in its second round of layoffs in the last year, STAT has learned.
Orna was part of a buzzy cohort of companies established in the wake of the Covid pandemic, planning to create new, more durable types of RNA-based medicines. It launched in 2021 and quickly garnered attention from Gilead subsidiary Kite Pharma, Bristol Myers Squibb, Novartis, and Merck.
The company, which is based in Cambridge, Mass., cut an undisclosed number of staff members in the last week, according to posts on social media. The company confirmed the layoffs in a statement, but did not say how many people were affected.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
